John Theurer Cancer Center Treats First Patient in US with Investigational New Treatment for Brain Cancer

What you need to know

John Theurer Cancer Center at Hackensack University Medical Center has treated the first patient in the country with DSP-0390, an investigational new drug for relapsed glioblastoma (GBM) and other anaplastic gliomas. 

DSP-0390, an investigational new agent developed by Cambridge, Massachusetts-based Sumitomo Dainippon Pharma Oncology, is an inhibitor of emopamil-binding protein (EBP), a molecule in cholesterol biosynthesis. DSP-0390 has not been approved by the U.S. Food and Drug Administration nor has its safety and efficacy been established.

This multicenter, global Phase 1/2 study is planned to enroll 70 patients at five brain tumor centers in the U.S. and Japan.

John Theurer Cancer Center is part of the Georgetown Lombardi Comprehensive Cancer Center. To learn more about this trial (NCT 05023551) and for more information about all brain tumor clinical trials occurring at John Theurer Cancer Center, call 551-996-5266 or visit clinical trials at John Theurer Cancer Center